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Renal fibrosis/sclerosis is the common final path-
way leading to end-stage renal failure. The renal fibro-
sis/sclerosis is characterized by increased proliferation
of fibroblasts and excessive accumulation of extracel-
lular matrix (ECM). The severity of tubulointerstitial
inflammation and fibrosis has been considered to be a
crucial determinant of progressive renal injury in patients
with various glomerulonephritides. Humoral factors re-
leased from infiltrating cells and injured tubular epithelial
cells cause further recruitment of inflammatory cells and
macrophages and the initiation of fibrogenesis in renal tis-
sues. Human mast cells are a heterogenous group of mul-
tifunctional tissue-dwelling cells with roles in conditions
as diverse as allergy, parasite infestation, inflammation,
angiogenesis, and tissue remodeling. Immunocytochemi-
cal studies have shown the presence within the tissues of
two mast cell phenotypes distinguishable by their neutral
proteinase content, the tryptase positive mast cell (MCT)
phenotype containing only tryptase, and the tryptase and
chymase positive mast cell (MCTC) phenotype contain-
ing both tryptase and chymase. MCT phenotypes appear
to be “immune system–related” mast cells with a pri-
mary role in host defense. On the other hand, MCTC
phenotypes appear to be “non-immune system–related”
mast cells with functions in angiogenesis and tissue re-
modeling rather than immunologic protection. Recently,
we reported the infiltration of tryptase- and/or chymase-
positive mast cells in both fibrotic and nonfibrotic areas
in the advanced stage of IgA nephropathy [1]. It appears
that the number of mast cells in the nonfibrotic areas may
be one of the predictive factors for the progression of
IgA nephropathy. These mast cells might induce fibrosis
and activate angiotensin II. Tubulointerstitial injury was
caused by diseases that initially affect the glomeruli or
renal vasculatures. Histopathologically, glomerular scle-
rosis, severe tubulointerstitial fibrosis, and mast cell infil-
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tration in the interstitium were observed in the advanced
stage of IgA nephropathy.
Recent findings have shown that monocyte chemoat-
tractant protein-1 (MCP-1), a chemotactic cytokine with
a high degree of specificity for monocytes and lympho-
cytes, may play an important role in the progression
of glomerular and tubulointerstitial injuries in experi-
mental and human glomerulonephropathies, including
IgA nephropathy and diabetic nephropathy [2]. A va-
riety of cell types, glomerular endothelial cells, mesan-
gial cells, tubular epithelial cells, and monocytes may
produce MCP-1 in response to inflammatory signals
such as cytokines (IL-1, TNFa, and INFc) and immune
complexes. Interleukin-8 (IL-8), a chemotactic cytokine
with a high degree of specificity for neutrophils, is pro-
duced by lipopolysaccharide (LPS)-stimulated human
peripheral blood monocytes and macrophages, fibrob-
lasts, and endothelial cells, in response to a wide variety of
endogenous and/or exogenous stimuli, such as inflamma-
tory cytokines. Among renal resident cells, both glomeru-
lar mesangial and proximal tubular epithelial cells can
produce IL-8 by proinflammatory stimuli such as LPS,
IL-1, and TNFa [3].
IgA nephropathy is well recognized worldwide as one
of the most common primary glomerulonephritides, and
is characterized by mesangial deposition of IgA in renal
specimens [4]. Since the original description by Berger
in 1968, several investigations have indicated the devel-
opmental and/or exacerbating factors for patients with
IgA nephropathy. It is not clear if only IgA deposits
in glomeruli are responsible for the glomerular inflam-
matory changes characteristic of the advanced stage of
IgA nephropathy, and the precise mediators signaling
lymphocytes and monocytes to migrate and colonize the
kidney are not known. However, it is clear that im-
munoglobulin deposition and/or complement activation
has a determinant role. It has been postulated that altered
T-cell function may play a major role in the pathogene-
sis of IgA nephropathy. The authors showed a significant
correlation between the levels of serum interleukin (IL)-
2 receptor and disease activities [i.e., levels of urinary
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protein, blood urea nitrogen (BUN), and uric acid]. We
also reported that the high levels of urinary IL-6 reflect
the glomerular inflammatory changes in patients with
IgA nephropathy [5].
On the other hand, glomerular infiltration of mono-
cytes/macrophages was observed in diabetic nephropa-
thy patients. An increase of MCP-1 expression in the
glomerular mesangial areas was also observed in strep-
tozotocin (STZ)-induced diabetic rats [6]. A recent
report demonstrated that urinary MCP-1 levels were sig-
nificantly elevated in patients with diabetic nephrotic
syndrome and its advanced tubulointerstitial lesions.
Moreover, MCP-1 positive cells were detected in the in-
terstitium of diabetic nephropathy patients [7]. In vitro,
high-glucose and glycated albumin has already been
reported to facilitate MCP-1 production from human
mesangial cells. IL-8 may also be enhanced by high glu-
cose in human endothelial cells and by glycated human
serum albumin in human retinal pigment epithelial cells.
URINARY LEVELS OF MCP-1 OR IL-8 AND
RENAL INJURIES IN PATIENTS WITH IGA
NEPHROPATHY AND DIABETIC
NEPHROPATHY
Noris et al [8] reported that urinary MCP-1 in patients
with active lupus nephritis was significantly higher than in
lupus patients studied in the inactive phase of the disease
or in healthy volunteers. Using a quantitative sandwich
enzyme-linked immunosorbent assay (ELISA), we stud-
ied patients with IgA nephropathy to determine if lev-
els of urinary MCP-1 might reflect disease activity. The
levels of urinary MCP-1 in patients with the advanced
stage of IgA nephropathy were significantly higher than
those in patients with the mild stage of the disease, or
in healthy control patients [9]. The results showed a sig-
nificant correlation between the levels of urinary MCP-1
and the disease activity (i.e., levels of urinary casts and
urinary protein). Thus, it was suggested that the measure-
ment of urinary MCP-1 is useful in evaluating the degree
of renal injuries and/or prognosis in patients with IgA
nephropathy.
We also examined the correlation among the levels
of urinary MCP-1 and IL-8, hyperglycemia, and renal
injuries in patients with type 2 diabetic nephropathy
[10]. The levels of urinary MCP-1, IL-8, protein excre-
tion, BUN, serum creatinine (s-Cr), glycohemoglobin
A1c (HbA1c), and fasting plasma glucose (FPG) were
measured in patients with type 2 diabetic nephropathy
and healthy adults as control. Diabetic nephropathy was
classified into three stages as follows: stage 1, normoalbu-
minuric; stage 2, microalbuminuric; and stage 3, macroal-
buminuric. All of the patients showed normal ranges in
renal function tests (BUN, s-Cr, and CCr). Levels of uri-
nary MCP-1 in all patients with diabetic nephropathy
were significantly higher than those in healthy adults (P <
0.05). The levels of urinary MCP-1 in patients with dia-
betic nephropathy increased gradually according to the
clinical stage of the disease. In contrast, the levels of uri-
nary IL-8 in patients with diabetic nephropathy increased
in stages 2 and 3. There was a significant correlation be-
tween the levels of urinary IL-8 and those of HbA1c.
High glucose may stimulate MCP-1 and/or IL-8 produc-
tion and their excretion into the urine independently of
the disease. It appears that IL-8 increased in the early
stage of diabetic nephropathy, and MCP-1 increased in
the advanced stage of the disease. It was concluded that
measurement of urinary MCP-1 and IL-8 may be useful
for evaluating the degree of renal injuries in patients with
type 2 diabetic nephropathy [10].
MCP-1 PRODUCTION ON GLOMERULAR
MESANGIAL CELLS AND PODOCYTES
It is considered that the glomerular and tubular epithe-
lial cells and monocytes may produce MCP-1 in response
to some cytokines (IL-1, TNFa, and INFc), immune com-
plexes, high glucose, or advanced glycation end products
(AGEs).
Glomerular mesangial cells
Mechanisms of allergic responses have been clarified
by extensive studies on FceR (IgE receptor) and FccR
(IgG receptor). Several studies have clarified that Fc
receptors (FcRs) lead to cell activation by multivalent
molecules with immunoglobulins, and may play a key
role in immunoglobulin-mediated inflammation such as
allergic diseases. Moreover, recent studies revealed that
FcR may play an important role in experimental glomeru-
lonephritis using FcRc chain knockout mice. On the other
hand, FcR for IgA (FcaR; CD89) might induce vari-
ous immunologic responses such as antibody-dependent
cellular cytoxicity (ADCC), and secretion of cytokines
and chemokines [11]. FcaR is a glycosylated membrane
protein of 50 to 75 kD, which is expressed mainly on
monocytes, neutrophils, and eosinophils. Previous stud-
ies reported that the FcRc chain is essential for signal
transduction via FcaR with IgA in transfected murine
B-cell and human monocytic cell lines [12]. A Spanish
group reported that FcaR on human cultured mesangial
cells might induce cell activation [13], although it is still
uncertain whether FcaR activation via the FcRc chain on
mesangial cells is actually induced.
Recently, we verified the physical association of FcaR
and the FcRc chain on human glomerular mesangial cells
and hypothesized their functional expressions [14]. The
objective of our study is to investigate whether FcaR
(with the FcRc chain) introduced on mesangial cells can
be activated and induce phosphorylation of the FcRc
chain or syk, and produce the MCP-1 via the mesangial
S-94 Tomino et al: Fibrosing factors in GN
ROS
P21 Ras
ERK
P65  P50 
Sp1
NF-kB1 NF-kB2 NF-kB3 AP1  GC region 
MCP-1 gene 
transcription
Nuclear
Membrane
RAGE
NAC
AFC
PD98059
Parthenolide
Mithramycin A 
Sp1 
RAGE-Ab
AGE, CML, S100
Fig. 1. Signaling pathway of MCP-1 produc-
tion stimulated by AGE, CML, or S100 in
podocytes.
machinery. Murine mesangial cell lines (SV40 MES 13)
were transfected with cDNA of human FcaR. Further-
more, we cotransfected some of the FcaR transfectants
with cDNA of the human FcRc chain. Tyrosine phospho-
rylation of the intramesangial proteins after FcaR cross-
linking was examined by immunoprecipitation. MCP-1
production from each transfectant stimulated with heat
aggregated IgA was determined by sandwich ELISA.
Two kinds of mesangial transfectants stably expressed
human FcaR with or without the FcRc chain (FcaR+,
FcaR+/c+). Phosphorylation of the FcRcchain and syk
kinase was detected in FcaR and FcaR+/c+ cells, but not
in untransfected cells. Aggregated IgA induced signifi-
cantly higher MCP-1 production in FcaR+/c+ than those
in FcaR or the untransfected control. The present study
demonstrated that FcaR and the FcRc chain could be re-
constituted in the mesangial cells and mediated MCP-1
production by aggregated IgA in a dose-dependent man-
ner. It appears that FcaR can be activated in mesangial
cells through their own machinery, although underlying
mechanisms for FcaR induction in mesangial cells remain
unclear. It is postulated that IgA immune complexes or
aggregated IgA may produce MCP-1 from the mesangial
cells under certain conditions in such cells.
Podocytes
MCP-1 is a member of the chemokine family regu-
lating macrophage recruitment, and is up-regulated in
diabetic nephropathy. Studies using human biopsy ma-
terials and animal models have shown the presence of
macrophage accumulation and MCP-1 expression in di-
abetic glomeruli, suggesting that MCP-1 may play an
important role in the development of diabetic glomeru-
losclerosis [15]. Previous studies showed that high glu-
cose and glycated albumin induce MCP-1 production
in cultured mesangial cells [16]. However, more recent
research found that mRNA expression of MCP-1 ap-
peared to be predominantly localized in podocytes of
diabetic glomeruli [15]. We still do not know what in-
duces MCP-1 production by podocytes. Furthermore, in-
tracellular mechanisms of MCP-1 up-regulation in the
podocytes remained unclear. Treating db/db mice, a spon-
taneous diabetes model mouse, with soluble receptor for
advanced glycation end products (sRAGE) prevented re-
cruitment of macrophages to the glomeruli, suggesting
that ligand receptors for advanced glycation end prod-
ucts (RAGE) may play an important role in MCP-1
production in the podocytes [16]. Expression of RAGE
is enhanced in the human diabetic kidney. Specifically,
RAGE is expressed at the base of podocytes in glomeruli,
but not to any appreciable degree in mesangial or en-
dothelial cells [17]. RAGE, a multiligand member of the
immunoglobulin superfamily [18, 19], engages ligands,
advanced glycation end products (AGEs), and members
of the S100/calgranulin family [20], is implicated in ex-
pression of the receptor itself, and amplifies proinflam-
matory response, leading to diabetic complications and
inflammation by a receptor-dependent mechanism [20,
21]. These responses are dependent on RAGE-mediated
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signals and expression. It has been shown that RAGE lig-
ation with its ligands results in the activation of multiple
signaling pathways in different lines of cells. However, lit-
tle is known about how ligands, after ligation with RAGE,
signal the podocytes involved in diabetic nephropathy
through macrophage migration and activation.
Up-regulation of local MCP-1 production is involved
in glomerular damage through macrophage recruitment
and activation in diabetic nephropathy. Recently, we in-
vestigated the role of AGEs in MCP-1 production by
podocytes and signaling events after RAGE activation.
MCP-1 was induced by AGE and carboxymethllysine
(CML) in a time- and dose-dependent manner as mea-
sured by RT-PCR and ELISA. Neutralizing antibody for
RAGE suppressed AGE- and CML-induced MCP-1 pro-
duction completely. Using laser-scanning confocal mi-
croscopy, we observed AGE and CML rapidly generated
intracellular reactive oxygen species (ROS) in podocytes.
Blocking of ROS using N-acetyl-L-cysteine abolished
CML and H2O2-induced MCP-1 expression. Phospho-
rylated extracellular signal-regulated kinase (ERK) was
found in podocytes incubated with CML, and was
prevented by N-acetyl-L-cysteine or 7′-amino 4 [trifluo-
rimethyl] (AFC). Both Western blotting and immunocy-
tochemistry results suggested that the nuclear factor-jB
(NFjB) and Sp1 were translocated into the nucleus af-
ter podocytes were incubated with CML for 60 minutes.
Parthenolide and mithramycin A, inhibitors of NFjB
and Sp1, respectively, abolished CML-induced MCP-1
gene expression in a dose-dependent manner. These re-
sults suggest that AGE and CML induce MCP-1 expres-
sion in the podocytes through activation of RAGE and
generation of intracellular ROS. NFjB and Sp1 regu-
late MCP-1 gene transcription directly (Fig. 1). It ap-
pears that the MCP-1 produced by the podocytes in a
hyperglycemic state may induce accumulation of mono-
cytes/macrophages and then stimulate the fibrosis in the
interstitial regions in patients with diabetic nephropathy
(submitted).
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